Table 1 Summary of respondent characteristics of the vial and PFS cohorts

Age (years), median [IQR]

57 [48, 66]

66

59 [49, 66]

120

0.34

Age at diagnosis (years), median [IQR]

46 [25, 59]

65

42 [25, 42]

118

0.99

Gender, n (%)

Female

39 (60.0%)

65

76 (63.9%)

119

0.61

Male

26 (40.0%)

43 (36.1%)

Bodyweight (kg), mean (± SD)

75.3 (± 17.2)

58

76.0 (± 17.5)

109

0.79

Underlying condition, n (%)

CVID

25 (47.2%)

53

37 (40.2%)

92

0.48

IgG Sub

13 (24.5%)

26 (28.3%)

DGS

2 (3.8%)

4 (4.4%)

SID

9 (17.0%)

10 (10.9%)

Other^a

4 (7.6%)

15 (16.3%)

Years since diagnosis, n (%)

< 2 years

4 (6.2%)

65

10 (8.5%)

118

0.22

2–9 years

34 (52.3%)

46 (39.0%)

≥ 10 years

27 (41.5%)

62 (52.5%)

Time on IgG, n (%)

< 1 year

3 (4.6%)

66

5 (4.2%)

120

0.56

1–2 years

67 (10.6%)

21 (17.5%)

2–3 years

4 (6.1%)

17 (14.2%)

4–6 years

21 (31.8%)

18 (15.0%)

≥ 6 years

31 (47.0%)

59 (49.2%)

Current treatment experience, n (%)

< 2 years

8 (12.1%)

66

21 (17.8%)

118

0.26

2–9 years

44 (66.7%)

64 (54.2%)

≥ 10 years

14 (21.2%)

33 (28.0%)

Antibiotics before IgG, n (%)

No

44 (77.2%)

57

79 (74.5%)

106

0.71

Yes

13 (22.8%)

27 (25.5%)

Antibiotics since starting IgG, n (%)

No

24 (36.9%)

65

50 (43.9%)

114

0.37

Yes

41 (63.1%)

64 (56.1%)